Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agents approved by the federal food and drug administration.
S04150 would expand New York’s opioid overdose response framework by replacing the narrower term “opioid antagonists” with “opioid reversal agents” and by requiring the Department of Health to make available any FDA-approved formulation and dosage of those products. The bill updates both the Mental Hygiene Law and the Public Health Law so that state programs, standing-order access, and related directories are not limited to naloxone alone or to products specifically approved by the department for this purpose.
The bill also directs the Office of Addiction Services and Supports, in consultation with the Department of Health, to maintain a publicly searchable directory of distributors of opioid reversal agents. That directory would include addresses, contact information, services offered, available products, special populations served, insurance accepted, hours of operation, and prevention-program contacts. The bill further defines “purchaser” broadly to include community organizations, municipalities, pharmacies, medical facilities, hospitals, and other entities accessing products through the state standing order.
If enacted, the bill would amend sections of the Mental Hygiene Law and Public Health Law to broaden state authority over opioid overdose reversal products and to standardize access to all FDA-approved formulations and dosages. It would require the state to cover the cost of any FDA-approved nasal naloxone product and allocate any cost above the highest-priced nasal naloxone product to the purchaser, while lower-cost products would be borne by the state. The measure would affect state agencies, distributors, pharmacies, municipalities, hospitals, community organizations, and other entities that purchase or dispense these products under the standing order system.
The available record shows no committee transcript or vote history, so there is no direct evidence of debate or formal support/opposition in the materials provided. Based on the bill’s sponsor list and subject matter, the proposal appears aimed at improving overdose prevention access and modernizing state law to reflect a broader range of FDA-approved reversal products. The overall framing is public-health oriented and likely intended to increase flexibility in procurement and distribution.
The main potential point of contention is cost and procurement responsibility. The bill requires the state to cover the cost of FDA-approved nasal naloxone products, but shifts any amount above the highest-priced nasal naloxone product to the purchaser, which could raise concerns for municipalities, nonprofits, hospitals, and other purchasers. Another possible issue is the expansion from naloxone-specific language to any FDA-approved opioid reversal agent, which may prompt questions about implementation, product availability, and whether the broader terminology could create administrative or budgetary complexity.